XBIT (XBiotech Inc.) stock: $1.89, $57.6M market cap, $109.5M cash, -$51.9M EV, $67.8M fully diluted market cap. Next expected readout: Jan-27. Lead program: Natrunix 400 mg (Rheumatoid Arthritis), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
XBiotech Inc. (“XBiotech” or the “Company”) is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. XBiotech was incorporated in Canada on March 22, 2005. The Company’s Internet address is www.xbiotech.com .
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
30.5M
Pre-funded warrants
0.0M
Options
5.4M
RSUs
0.0M
Warrants
0.0M
Converts
—
Conv preferred
—
ESPP reserve
—
FDSO
35.9M
Cap table as of 2026-08-13.
Price history
Loading XBIT daily closes…
Loading price history…
Next catalyst
Natrunix 400 mg · Feb 26 - Apr 9 in 16 wks · Phase 2 · Rheumatoid Arthritis
Recently reported
vilamakitug Phase 2Positive · 2026-10-19
TASKIN
Primary: 12-month overall survival at the landmark analysis under a Simon two-stage design; pre-specified primary efficacy success criterion of 42 or more surviving patients in the vilamakitug experimental arm — 49 of 80 evaluable patients (61.3%) in the vilamakitug arm were alive at 12 months, surpassing the protocol-defined threshold of 42 or more surviving patients required to establish efficacy; in the control arm, 44 of 79 evaluable patients (55.7%) were alive at 12 months
· Median progression-free survival was 5.9 months for the vilamakitug arm versus 5.6 months for the control arm, with a 12-month PFS rate of 25.0% versus 21.0% (log-rank p = 0.42)
· The 12-month time to strategy failure (TSF) rate was 31.2% in the vilamakitug arm compared to 20.3% in the control arm (log-rank p = 0.17)
· Prospective exploratory subgroup of right-sided primary tumors (n = 37): 62% reduction in the risk of death versus control (Hazard Ratio [HR] = 0.38; 95% CI: 0.14-0.99; Cox p = 0.047, log-rank p = 0.038) through 12 months
· Right-sided subgroup TSF: 61% reduction in the risk of treatment strategy failure versus control (HR = 0.39; 95% CI: 0.18-0.85; Cox p = 0.017, log-rank p = 0.014) through 12 months
Safety: Vilamakitug demonstrated high feasibility in combination with chemotherapy, showing a 96.4% mean compliance rate for trifluridine/tipiracil and only a 1.3% permanent discontinuation rate for vilamakitug/placebo; no adverse-event table was disclosed in the release
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Stage not disclosed · ActiveModality: monoclonal antibody
Target IL-1-alpha
Indications
Pancreatic cancer (oncology)(Stage not disclosed)
Rheumatology(Stage not disclosed)
Status note True Human antibody targeting IL-1-alpha. In 2021 the Company commenced a randomized, double-blinded, placebo-controlled clinical study in pancreatic cancer. A clinical rheumatology program was launched in August 2023 (233 subjects enrolled in a double-blind, placebo-controlled study). Clinical stage not stated in the excerpts.
Hutrukin
Stage not disclosed · ActiveModality: monoclonal antibody
Indications
Brain injury following reperfusion(Stage not disclosed)
Status note True Human antibody candidate therapeutic to reduce brain injury occurring after reperfusion; IND filed in 2022. Clinical stage not stated in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.